Overview

• The $55 million upfront sale of Tecelra and the clinical-stage therapies lete-cel and uza-cel includes up to $30 million in milestone payments tied to regulatory and commercial goals.
• All employees involved in the development and commercialization of the divested assets will transfer from Adaptimmune to U.S. WorldMeds.
• Adaptimmune will cut 62% of its remaining workforce after closing, following a 29% reduction earlier this year to conserve cash.
• Tecelra, the first TCR cell therapy approved for synovial sarcoma in 2024, generated just over $4 million in Q1 revenue against nearly $29 million in R&D spending.
• The transaction is set to close by week’s end, leaving Adaptimmune focused on its two preclinical T cell platforms.